3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Advanced Solid Tumors
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
talazoparib
×
Clear all
No trials found.